Sanofi Signs Benitec's closest competitor Voyager for $845M, page-29

Five sites for nine patients? Sounds expensive and reactive now.

"Although the inclusion criteria for this Phase I/II(a) trial are appropriately strict due to the non-withdrawable nature of TT-034, once a suitable safety profile has been established for the therapeutic, many of the trial exclusion parameters will be relaxed, enabling the treatment of much larger groups of patients."

I think this was the statement that had me thinking they might extend. I took safety profile to be good by cohort three and perhaps a few more people added to the later cohorts. Now I see he meant Phase 2B. These sites will probably stay on board for 2B.